We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NTRS:NASDAQNorthern Trust Corporation Analysis

Data as of 2026-05-27 - not real-time

$169.94

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Northern Trust (NTRS) is trading at $169.94, comfortably above its 20‑day SMA ($164.23) and 50‑day SMA ($154.74) while still below the 200‑day SMA ($140.31), indicating a strong bullish alignment. The MACD line sits just above its signal line, the histogram is positive, and the RSI at 69 points to momentum that is approaching overbought territory. Volume is trending lower, but the stock remains supported at $158.98 and faces resistance near $170.24, a level it is currently testing. Fundamentally, the company posted 13.9% revenue growth, a solid operating margin of 31.7%, and a dividend yield of 1.88% with a modest 33% payout ratio, suggesting dividend sustainability. With a DCF fair value of $186.43, the market price reflects roughly a 6% discount, supporting an undervalued view despite a PE slightly above the industry average. The balance sheet shows ample cash ($11.8B) against debt, a beta near 1.1, and 30‑day volatility of 28%, highlighting moderate market risk. Overall, the technical setup is bullish but nearing short‑term resistance, while the fundamentals provide a growth‑oriented, dividend‑supportive platform for medium‑ to long‑term investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price approaching resistance at $170.24
  • RSI at 69 indicating near‑overbought conditions
  • Bullish MACD confirming short‑term momentum

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value $186.43 implies ~6% upside
  • 13.9% revenue growth and strong operating margins
  • Sustainable dividend yield of 1.88% with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Robust cash position and diversified asset‑servicing business
  • Consistent profitability and solid ROE (14.5%)
  • Long‑term dividend sustainability and growth orientation

Key Metrics & Analysis

Financial Health

Revenue Growth13.90%
Profit Margin22.36%
P/E Ratio17.8
ROE14.46%
ROA1.10%
P/B Ratio2.6
Op. Cash Flow$2.5B
Industry P/E16.7

Technical Analysis

TrendBullish
RSI69.1
Support$158.98
Resistance$170.24
MA 20$164.23
MA 50$154.74
MA 200$140.31
MACDBullish
VolumeDecreasing
Fear & Greed Index91.14

Valuation

Fair Value$186.43
Target Price$171.00
Upside/Downside0.62%
GradeUndervalued
TypeGrowth
Dividend Yield1.88%

Risk Assessment

Beta1.07
Volatility28.26%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.